Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. The company is headquartered in Reno, Nevada and currently employs 40 full-time employees. The company went IPO on 2025-03-06. The firm is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. The company has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The firm offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.